Sold as Neptazane. Every FDA application for this active ingredient: 1 branded and 8 generic.
As of Nov 14, 2026, FDA lists 9 applications for Methazolamide (sold as Neptazane), first approved Jan 26, 1959, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Methazolamide | Part D | $9.0M | -6% | 11,914 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Use of Methazolamide to Lower Intraocular PressureGlaucoma, Open-Angle · University of Colorado, Denver | Phase 4 | Active, not recruiting | Aug 11, 2022 |
| Jan 26, 1959 | NeptazaneNDA 11721 · New dosage form | Lederle | 9 | Discontinued |
| Jun 30, 1993 | MethazolamideANDA 40001 | Ani Pharms | 9 | Marketed |
| Jun 30, 1993 | MethazolamideANDA 40036 | Chartwell Rx | 10 | Marketed |
| Jan 27, 1994 | MethazolamideANDA 40062 | Pharmobedient | 3 | Marketed |
| Aug 28, 1996 | MethazolamideANDA 40102 | Pharmobedient | 0 | Discontinued |
| Jul 17, 1997 | MethazolamideANDA 40011 | Applied Anal | 0 | Discontinued |
| Oct 5, 2018 | MethazolamideANDA 207438 | Bausch And Lomb Inc | 0 | Marketed |
| Oct 18, 2022 | MethazolamideANDA 215615 | Tagi | 0 | Marketed |
| Feb 9, 2026 | MethazolamideANDA 217408 | Ajanta Pharma Ltd | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
